HOME >> BIOLOGY >> NEWS
Researchers discover method for identifying how cancer evades the immune system

One of the fundamental traits of a tumor how it avoids the immune system might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumors immune signature, could be useful for diagnosing and treating specific cancers.

In the July 1 issue of Clinical Cancer Research, a publication of the American Association for Cancer Research, the researchers describe a means for determining which genes have been altered in a tumor to allow it to evade the bodys natural defenses. In time, the researchers believe such analysis could become a standard practice in cancer diagnosis and treatment.

The implication is that once you know the mechanism by which tumors evade the immune system, you can match that tumor to available therapies, said senior author Alan L.Epstein, M.D., Ph.D., professor of Pathology at USCs Keck School of Medicine. First, we find the genetic changes that allow a tumor to defeat the immune system, then we can apply therapies that compensate for these genetic alterations.

According to Epstein, tumors are notorious for demonstrating a broad array of genetic and biological variations. Their differences vary widely between cancer types, even between subcategories within a particular type of cancer. However, while the genetic variations that comprise an immune signature are complex, the researchers discovered that a small subset of genes is integral in explaining immunological behavior.

Using real-time PCR (rtPCR), a high-speed gene amplification technique, Epstein and his M.D./ Ph.D. student, Rebecca Sadun, screened tumors to identify 14 pro-immunity genes, which tumors downplay, and 11 key anti-immunity genes, which tumors promote. They studied the expression of these genes in five mouse tumor models for breast cancer, leukemia, colon cancer, lung cancer a
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
2-Jul-2007


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers use adult stem cells to create soft tissue
10. Researchers find gene that spurs development of the epididymis
11. Researchers isolate new risk marker for overweight children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... 05, 2020 , ... Regenative Labs has received approval from the Centers for ... them the first Wharton’s jelly allografts to be assigned a Q code and be ... the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical ... that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and ...
(Date:7/2/2020)... ... 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , a ... for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology Association ... of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 single ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... 2020 , ... Medial EarlySign , a leader in ... high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced ... in order to identify and prioritize patients for care. , Combining Centric’s management ...
(Date:7/10/2020)... ... 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will ... SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast Inc. , developers ... announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The ... of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 ...
Breaking Biology Technology:
Cached News: